Structure Therapeutics
GPCR
48 hedge funds and large institutions have $699M invested in Structure Therapeutics in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 4 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
102% more capital invested
Capital invested by funds: $346M → $699M (+$353M)
26% more funds holding
Funds holding: 38 → 48 (+10)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
2.99% more ownership
Funds ownership: 13.45% → 16.43% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$33.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.7M |
| 3 |
CC
Casdin Capital
New York
|
+$8.97M |
| 4 |
DM
Deerfield Management
New York
|
+$7.08M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$5.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$7.54M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.08M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.78M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
51
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$19.2K | -805 | Closed |
|
52
Morgan Stanley
New York
| – | -$262 | -11 | Closed |
|
GPCR Hedge Fund Activity: Q2 2023 in Review
48 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q2 2023, worth a combined $699M — up 102% from $346M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GPCR positions and 4 closed out — a net gain of 10 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Monashee Investment Management, adding an estimated $33.7M. The largest seller was Janus Henderson Group, cutting an estimated $7.54M.
- 48 institutional investors held Structure Therapeutics (GPCR) as of Q2 2023, up from 38 in Q1 2023.
- Funds reported $699M of Structure Therapeutics stock for Q2 2023, up 102% quarter-over-quarter.
- 14 funds opened new Structure Therapeutics positions in Q2 2023 and 4 closed out, a net change of +10 holders.
- The largest Structure Therapeutics buyer in Q2 2023 was Monashee Investment Management, an estimated $33.7M added.
- The largest Structure Therapeutics seller in Q2 2023 was Janus Henderson Group, an estimated $7.54M sold.
Based on aggregated 13F filings for Q2 2023.